See What HealthDay Can Do For You
Contact Us

Dual Action Antibody Reverses Menopausal Bone Loss

FSH antibody attenuates bone resorption, stimulates bone formation in mouse model

THURSDAY, Aug. 23 (HealthDay News) -- An antibody can reverse bone loss in menopausal mice by both blocking bone breakdown and stimulating bone formation, according to an experimental study published online Aug. 20 in the Proceedings of the National Academy of Sciences.

Building on previous results showing that follicle-stimulating hormone (FSH) directly stimulates bone loss by osteoclasts, bypassing the estrogen pathway, Ling-Ling Zhu, from the Mount Sinai School of Medicine in New York City, and colleagues tested the ability of a polyclonal antibody to a peptide sequence within the receptor-binding domain of the FSH β-subunit to block osteoclast formation in ovariectomized mice, a model of menopause.

The researchers found that the FSH antibody bound FSH specifically, and, in vitro, prevented its action on osteoclast formation. When injected into mice, FSH antibody reduced bone loss by inhibiting bone resorption and, unexpectedly, stimulating bone formation. Mesenchymal cells from the treated mice had increased osteoblast precursor colony counts, and further experiments showed that mesenchymal cells contained receptors for FSH.

"Overall, the data prompt the future development of an FSH-blocking agent as a means of uncoupling bone formation and bone resorption to a therapeutic advantage in humans," Zhu and colleagues conclude.

One author is a named inventor on a patent application related to osteoclastic bone resorption.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.